Search results

Ilonov develops first-in-class biotherapies unlocking the muscle secretome to counter metabolic dysfunction. Our lead assets, based on human-centric discovery, preserve mitochondrial health, maintain tissue function and reduce chronic inflammation, addressing the unmet need in diabetes and MASH.

RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness and aims to restore vision and transform the lives of patients worldwide.

Headquartered in Switzerland with global operations, Space Peptides provides end-to-end pharmaceutical Peptide CRDMO services - covering discovery, process development, and GMP manufacturing. In addition, our portfolio comprises a broad range of generic Peptide APIs.

AzureCell is a Swiss regenerative cell therapy company leveraging two decades of pioneering neuroscience and cell‑engineering research at the University of Geneva to advance next‑generation allogeneic cell‑replacement therapies for the brain.

Streamlining complexity: with 15+ years experience (EU, US and Far East) in Oncology, Rare Diseases and Quality of Life Assessment, Naexture provides ad-interim leadership roles in Clinical Operations and Program Management to end-to-end operationalize clinical research programs.

Stallergenes Greer is a fully integrated global healthcare company specialising in the research, diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services.

CALDRE is a Switzerland based biotech spin-out focussed to revolutionize the way cholestatic-and fibrotic diseases are treated. We develop precise, liver-directed GalNAc-siRNAs to restore bile flow and prevent fibrosis - placing CALDRE in the fast-growing RNA-therapeutics segment of biotech.

Almac provides the most comprehensive global clinical supply chain solution in the marketplace. Guided by our extensive supply experience, we provide the physical resources and supportive technologies that ensure your clinical supply chain continually delivers across the globe.

SYDRA AG (Zurich) is a longevity biotech using a phenotype-first, AI-assisted “Hit-to-Target” early drug discovery platform. We discover small molecules (geroprotectors), validate in vivo (worms – aged mice), then map MoA to build partner-ready drug assets; plus science-backed supplements.

Jantar is a clinical R&D company in the field of chronic rhinosinusitis. Its product is a nasal spray of dicholine succinate. Clinical efficacy has been demonstrated by well-documented case studies which showed that the drug relieves all symptoms of the disease. A PCT patent has been filed.

Mabylon is a clinical-stage company leading innovation in human-derived antibody therapeutics for severe allergies, inflammation, and neurological disorders. MY006, our first-in-class multi-specific antibody therapeutic for peanut allergy, is tackling the growing food allergy market.

Enantios is a Swiss startup revolutionizing molecular characterization with in-solution structural analysis of chiral complex molecules and Antibody drug Conjugates (ADCs). Enantios delivers solutions for quality control and drug development in pharmaceutical, biotech, and chemical industries.

As a health company, we envision empowering global well-being by pioneering biological solutions drawn from nature. Our mission: Unlock the full potential of exDNA across diverse indications. Our AND Technology Platform has the primary focus on controlling disease caused by pathogenic bacteria.

Ultimate Medicine is a Swiss preclinical biotech focused on preserving independence and quality of life for patients with Alzheimer's disease and other dementias.

TheraPPI Bioscience, a preclinical biotechnology company developing small molecules modifying protein interactions in oncology, rare diseases and inflammation

The Future Rewritten: Unlocking Genome Editing. By fusing directed evolution, high-throughput characterization, and AI, Nerai creates novel CRISPR editors, more precise and more powerful, making gene editing safer and accessible to more patients.

Tridek-One is a biotech start-up developing first-in-class CD31 agonist modalities designed to restore the immune balance.

Beech Biotech is developing a novel treatment for preeclampsia, an severe unmet medical need that takes the lives of 70,000 women and 500,000 babies each year. The company is developing a novel placenta-impermeable antibody and works with a network of expert industry consultants and contractors.

Umlaut.bio develops first-in-biology small molecules focusing on tRNAs that protect signalling transduction mRNAs from degradation. Addressing this previously undrugged fundamental biochemical principle  could be able to selectively prevent the growth of cancer as well as  proinflammatory cells.

MicThera harnesses microbes to discover breakthrough therapeutics, leveraging microbial bioactive molecules -synthetically produced- to overcome therapy resistance. Our discovery platform unlocks microbial-inspired therapeutics to develop innovative treatments.

A swiss-based company developing therapeutics for chronic inflammation. We are engineering novel bi-functional Duokine therapeutics, rationally designed to simultaneously target distinct immune cell populations and disease-relevant pathways.

Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development.

metaLead is an early-stage life science spinout from the University of Zurich, supported by reputable investors, i.e., BaseLaunch. We aim to revolutionize the treatment landscape for metal-related diseases, starting with Wilson disease, leveraging our platform of novel, rationally designed peptides.

Leman Biotech is a clinical-stage biotech advancing immunotherapy via metabolic reprogramming. Its META 10 platform reverses T-cell exhaustion to unlock unprecedented efficacy and durability in oncology and autoimmune diseases, delivering a highly effective, scalable, and accessible approach.

Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of neurological disorders. Our drug discovery and development platform identifies and develops allosteric modulators.

Abbmira therapeutics is a Basel based biotech founded by experience scientists and entrepreneurs in September 2024. Abbmira develops first-in-class small molecules to fine-tune native immunity to treat difficult-to-treat cancers and chronic diseases.

InVirtuoLabs is pioneering the next-generation laboratory by integrating AI with molecular simulations to revolutionize drug discovery. Our platform generates up to 1 billion novel molecules per day, rapidly screening and identifying the most promising ligands for specific biological targets.

Avenza Consulting has been created to support pharma, biotech companies, startups to develop and grow by offering Strategic Consulting, R&D services to foster innovation, Program & Portfolio Management to optimize projects, and Operational Excellence to streamline processes.

Signal26 Biotherapeutics is a biotechnology startup dedicated to advancing a novel antibody for treating psoriasis. In collaboration with interdisciplinary experts, we lead research into interleukin 26 (IL-26) and its role in the signalling pathways involved in autoimmune disorders.

Juvion develops advanced therapeutics aimed at preserving neuron-muscle connectivity, tackling immobility and sarcopenia to extend healthspan.

Release Therapeutics is a preclinical-stage BioMedTech company developing the first cell macroencapsulation technology specifically designed to get therapeutic proteins where they are needed most, in the CNS and beyond.

Enzene is a fully integrated CIDMO with sites in Pune (India) & New Jersey (USA), offering discovery to commercial supply. Its EnzeneX™ FCCM™ tech leads next-gen biologics, aiming to cut mAb costs below $40/g by 2025. Learn more at www.enzene.com.

BeOne Medicines is a global oncology company developing innovative, affordable, and accessible cancer treatments worldwide. We expedite development of our diverse pipeline of novel therapeutics through strong internal capabilities and collaborations. Our 11,000 colleagues span six continents.

Justin Stindt Consultants is a consulting firm specializing in Strategy & Market Access advisory services for the pharmaceutical, biotech and medical device industries.

We are offering worldwide professional medical writing and related services to the pharmaceutical (human & veterinary), biotech, medical device and other industries, CROs and academic institutions. With over 20 years of experience in the field, we guarantee the best possible medical writing.

Founded in mid-2022, T-Oncology is a Swiss biotech startup dedicated to transforming cancer treatment through innovative therapies. Our Mission: Give hope to patients by creating advanced therapeutics that offer safe and more effective treatment options, affordable for patients worldwide.

Amporin is developing a new class of small molecule amyloid pore inhibitors as the first potential acute oral drugs to stop and reverse the progression of deadly degenerative diseases. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease.

Procavea Biotech is an ETH Spin-off company developing an innovative protein-based RNA delivery platform. Our focus is to generate siRNA therapeutics in extrahepatic disease areas that are currently unreachable.

Access2Health partners with biotechs, providing flexible, cost-effective support to maximise asset value. We offer strategic guidance in market potential, evidence generation, pricing, and value strategy, helping biotech leaders make informed decisions that strengthen their position with investors.

ICE Biopharma has 2 core businesses: in-licensing specialty and rare disease drugs for Europe and Canada, and operational consultancy to companies evaluating international Commercialization options. We want European and Canadian patients to have access to the breakthrough therapies they deserve.

Xcube.bio invests capital, knowledge and capabilities in the European market entry of late-stage biopharmas, with the objective to create partners' own commercial footprint and revenue streams. We offer a unique value proposition that open and de-risk the European market for innovative therapies.

Allegria Therapeutics was founded in Basel in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches around biological targets that selectively modulate mast cells, Allegria plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases.

Complyomics supports Life Sciences companies in core areas as: Build and maintain robust Quality Systems in compliance with regulatory requirements. Provide externalized QA. Audits Develop expertise in Bioanalytical / Analytical areas Identify / assess / supervise sub-contractors Due diligence

Tandem Therapeutics (Spin-off ETH Zurich & PSI) is tackling the growing unmet medical need in treating fibrosis with precision extracellular matrix targeting. Our novel peptide drug conjugates selectively target mechanical changes in the fibrotic extracellular matrix to potentially halt progression.

ARTBIO is a clinical-stage radiopharmaceutical company focused on developing a new class of alpha radioligand therapies (ARTs) to transform cancer treatment. ARTBIO's approach centers on utilizing the alpha-emitting isotope Pb212 to target cancer cells while minimizing damage to healthy tissues.

HekeTiss, a UNIGE/HUG spin-off, enhances lives by pioneering cell-therapy treatments for ulcerative skin conditions. Innovating for a healthier tomorrow.

FatiAbGen International is the Swiss subsidiary of FatiAbGen Co. Ltd., established in Korea in 2020. We engineer best in class antibodies tailored for multiple modalities such as ADCs and bi-specifics. We then develop targeted molecules to address high unmet need diseases in oncology and immunology.

NewBiologix is a company developing a proprietary and breakthrough platform for the advanced engineering of cell lines. The company is committed to improving the production of viral vectors used in gene therapy by combining an innovative bioinformatics platform with advanced R&D experimentation.

Luminance Health is a premium life science consultancy providing personalized support across the entire value chain. We provide cross-functional strategic and hands-on support to develop, register, market and bring innovative products to market.

Curie.Bio is a $1.2B VC founded to discover and develop important new medicines. We do that by investing directly into existing companies, creating focused spinouts, and helping founders build companies from scratch. Our team of >80 full-time drug hunters provides hands on support to founders.

APR Applied Pharma Research s.a. (wholly owned by Relief Therapeutics Holding AG, SIX: RLF.SW), is a B2B Swiss-based international biopharma focused on development and global commercialization of innovative, patent protected products designed to address unmet needs.

At Stämm we develop accessible, plug & play biomanufacture solutions; allowing an automatized, continuous and more efficient production of biologics and cell therapies while managing media conditions. We have reinvented biomanufacturing by providing an alternative to the known biomass production.

Menarini Biotech (“MBH”) is a fast-growing, agile, fully integrated CDMO for biologics. Established in 2003, MBH's mission is to provide fast and efficient, yet very customer-centric, world-class, high-quality, services for biotech companies. Our Q system complies with AIFA/EU GMP requirements.

Solvias is a Contract Research, Development & Manufacturing Organization We offer comprehensive, high quality and fast, complex small molecule API early phase development and GMP-manufacturing by ensuring the interplay of scientifically outstanding experts in every required individual discipline.

Salvina Therapeutics is developing antibodies with a novel approach for targeting TNF and TNF superfamily members with the aim of improving their safety and efficacy, and facilitating the generation of novel bispecific therapies.

Porton Pharma Solutions, a global company with R&D, and GMP-compliant manufacturing facilities across US, EU and China, provides customer-centric innovative, and reliable CDMO solutions for Small Molecules, Tides, Biologics and Conjugates (ADCs, PDCs, etc.) from pre-clinical to commercial stage.

Bavarian Nordic is a fully integrated vaccine company focused on the development, manufacturing and commercialization of life-saving vaccines. Our manufacturing site for oral vaccines is located in Thörishaus, 15 km southwest of Bern.

Altorfer Engineering is a specialized contractor and consulting company. We provide expertise in engineering and project management services, and technology transfers. Our focus is on developing and managing aseptic formulation and fill-finish processes tailored to your receiving sites.

Blueprint Medicines is a global precision therapy company inventing life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, our medicines selectively target genetic drivers, with the goal of staying one step ahead of disease.

Infinity Communications works with start-up and growth-stage healthcare companies to deliver insights-driven, strategic communications. We add value by developing content and material to raise your company profile, attract new investors and engage audience groups across the health ecosystem.

B Squared helps biotech and cell & gene therapy companies navigate complex CMC, manufacturing, and sourcing challenges. We bring hands-on expertise, real-world solutions, and a no-nonsense approach to getting things done. www.bsquared.ch

CELLnTEC technologies enable science and industry to develop innovations in stem cell research, regenerative medicine, cell-based therapies, and beyond. The company is a pioneering developer of chemically defined, animal and human components-free precision media.

Caland SA provides a professional, confidential, competitive and impeccable service of pharma-grade CO2 extraction, distillation and cannabis formulation based on GMP requirements. A modern production line, coupled to a qualified ERP, ensures uncompromising quality of all products and services.

Curare specializes in translational and clinical pharmacology, increasing confidence in therapeutics translation from the bench to clinical proof of concept, and enhancing early stage decision-making.Expertise tailored to your needs, from small biotech to pharma.

MRGN Advisors was established in 2015 to advise CEOs, boards and investors on portfolio strategy, commercial and market access development, partnering and investment advisory in pharma, biologicals, vaccines, med tech and healthcare IT. Our motto: Even monkeys fall from trees — Japanese Proverb

Our goal is to deliver innovations in health care through cutting-edge tech and research, addressing challenges in antimicrobial therapies to improve patient outcomes. We are committed to delivering superior treatments that promote healing and improve quality of life globally.

Floratek Pharma is focused on drug discovery and preclinical development, enhancing the healing power of plants through the optimisation of existing natural compounds. The company pipeline comprises of anti-cancer and neurodegenerative disorder therapies as well as anti-aging dietary enhancements.

I work WITH my clients as a freelance science business development project manager. Having said that, Boehler Life Science Advice is not typical consultancy, even though strategic planning and execution is an important part of supporting my clients.

Orio Therapeutics developed a technology based on protein engineering allowing to integrate a "built-in" delivery systems into any therapeutic protein. Orio Therapeutics has set as a priority for their first product the development of a cardioprotective drug for heart attack patients.

VACCENTIS AG is a Zurich-based investment company focused on the biotech and pharmaceutical sector. The entire research, production and sales activities are carried out by two highly specialized subsidiaries, VCC MEDICAL and FBM- Pharma, which focus on special methods of personalized medicine

InkVivo Technologies combines its patented biomaterial platform with advanced manufacturing technologies to fabricate novel delivery systems that ensure controlled and prolonged release of active ingredients (e.g., small molecules, biologics and micronutrients).

Provectis Healthcare AG is a global healthcare company based in Basel and the commercial partner of choice to the innovative biopharma. We advance the innovation through launch, commercialization and brand building in Europe, Middle East and Asia.

FimmCyte is developing disease modifying therapies for chronic diseases through the direct elimination of diseased cells. FimmCyte has a pipeline of assets two of which are about to begin IND enabling studies, one for endometriosis and the second for organ fibrosis.

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation.

Tenpoint Therapeutics is a global, clinical-stage biotech company developing treatments to rejuvenate vision in the aging eye. Its pipeline includes treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy.

Amphilix AG is a Basel-based biotech developing next-generation radioligand therapies using a proprietary 3D linker platform and small-molecule ligands. Its clinical-stage lead AMX-0053 targets a protein for colorectal cancer and is ready for First-in-Human imaging. The company seeks CHF 9m Seed.

Toxicology Consultant with >25 years of experience in the Biopharmaceutical Industry. I support Startup and Biotech Companies to advance their projects into the clinical phase. Get in touch to discuss your project when you have a shortage of nonclinical and toxicological expertise.

Oncodesign Services is a leading CRO specializing in drug discovery and preclinical services in (immuno-)oncology, autoimmune, inflammation and infectious diseases, through integrated capabilities in medicinal chemistry, DMPK, pharmaco-imaging, bioanalysis, and in vitro/in vivo pharmacology.

We identified a novel immuno-oncology target through bacterial metabolites that activate tumor-residing macrophages, triggering a potent anti-tumor response. By leveraging natural metabolic processes, we develop small molecule therapies to enhance the body’s native immune defense against cancer.

ACM Biosciences AG is a subsidiary of ACM Biolabs PTE Ltd. Singapore. Its purpose is to internationalise its development activities. It leads all clinical and regulatory activities of its pipeline programs and coordinates business development discussions with potential partners.

Cellerys AG is a clinical stage biotechnology company, developing immune tolerance therapeutics for the treatment of multiple sclerosis (MS). Antigenic peptides identified from MS patients are coupled to autologous red blood cells which, when reinfused, restore immune tolerance. in 2021 the company entered a

Preclinical Safety/Toxicology and Strategic Regulatory Consulting for biotech startups with focus from preclinic to first-in-human trial.

Alloy Therapeutics is a biotechnology ecosystem company democratizing access to tools, technologies, and services for discovering and developing therapeutic biologics across six modalities, including antibodies, TCRs, genetic medicines, peptides, cell therapy, and drug delivery.

EvlaBio is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a Therapeutic Monoclonal Antibody (mAb) targeting unphysiological FGFR4/FGF23 cardiac overdrive in the setting of chronic kidney disease (CKD).

MEDICE has always developed and produced medicinal products almost exclusively at the Iserlohn site and concentrates in the prescription area on CNS, renal medicine and dialysis medicine. Salmon Pharma is the Swiss subsidiary of MEDICE.

We are specialized in processes optimization and validation, GMP and ISO compliance aspects, quality systems, risk analysis, CE marking, equipment qualification, project management, etc.

Azafaros is a clinical-stage biotech company addressing rare genetic lysosomal storage disorders with oral small molecules, including nizubaglustat. Our focus is on developing disease-modifying therapies for patients with, among others, GM1 and GM2 gangliosidoses, and Niemann-Pick Type C disease.

AlphaMol is an AI-based bio-pharmaceutical company focusing on G protein-coupled receptor drug discovery. The Cofounders of AlphaMol are leading scientists in the area of GPCRs. Many essential molecular mechanisms and biotechnology were invented by the members of AlphaMol.

PDC Therapeutics is a clinical-stage biotech start-up developing targeted Polymer-Drug Conjugate technologies with an optimal therapeutic index. The proprietary Sagitta® biodegradable conjugation platforms help discover and develop therapies with no compromise with a versatile targeting capability.

Founded in 2018, Peptone specializes in novel therapeutics for Intrinsically Disordered Proteins (IDPs), linked to inflammatory diseases such as cancer. Their approach integrates biophysics, supercomputing, and machine learning, now advancing in their labs.

SEAL Therapeutics develops an innovative gene therapy approach that overcomes the functional defects causing LAMA2-related muscular dystrophy. The approach involves AAV-based delivery of specifically designed artificial linker proteins to compensate for the missing laminin-alpha 2 in muscle fibers.

Thermo Fisher Scientific Lengnau is a state-of-the-art multi-purpose manufacturing facility for the production of biologics. It offers highly flexible biomanufacturing technologies, from development to large-scale production with single use and stainless steel equipment to meet our customer needs.

Tigen is a Swiss clinical stage biotech company developing cell therapies to cure cancer. A disruptive catalyst, combining a unique culture with a multidisciplinary set of world-class capabilities and a long-term perspective to accelerate access to novel T-cell therapies for patients and society.

iQone is a Swiss specialty pharma company for oncology, immunology and rare diseases. We commercialise innovative and biosimilar medicines with 7 marketed and 9 late-stage products. iQone can support partner products directly in the 5 major EU + CH markets, and indirectly in the rest of Europe. iQone Healthca

MedXCell is a Swiss biotech venture builder led by entrepreneurs and backed by private investors. MedXCell's portfolio includes pre-clinical companies CYTEA BIO and Soteria Bio.

Landmark BioVentures AG, founded in 2021 and headquartered in Basel, Switzerland, is an integrated and agile biotech hub-and-spoke company. LBV takes a unique model focused on lean operations, smart capital allocation, and diversified nexus of 7 companies developing 10 first-in-class therapeutics.

MPC Therapeutics is the leading biotech company developing Mitochondrial Pyruvate Carrier (MPC) targeted therapies. MPC is an extraordinary target that plays a key role in metabolism. We are committed to delivering novel treatments in cancer immunotherapy, kidney diseases and neurodegeneration.

We are a clinical-stage biotech company developing first-in-class small molecules to induce mitophagy, i.e. the process of replacing damaged mitochondria. We address age-related and chronic diseases including CNS disorders to treat cognitive impairment..

IDEOGEN Group is a family owned Swiss pharmaceutical group, providing global access to specialty medicines for unmet medical needs. We specialize in the commercialization of specialty medicines in Europe with challenging and evolving healthcare dynamics.

Somagenetix is a spin-off from the University of Zurich leveraging scientific, clinical & commercial expertise to solve unmet medical needs. With our gene therapy platform, we aim at becoming a leading company with first & best-in-class treatments for phagocyte-related disorders.

Mosanna is committed to improving patient outcomes and quality of life in high unmet need diseases, carefully selecting innovative medicines for further development. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.

Adoram Therapeutics is developing a suite of small molecule allosteric modulators for different indications. Our primary asset in the preclinical stage, is a negative allosteric modulator (NAM) of a clinically validated immuno-oncology target - the adenosine 2A receptor (A2AR).

Aukera builds a discovery engine that allows designing new classes of drugs to selectively target different branches of the mTOR pathway. The lead program selectively targets mTOR complex 1 to treat rare diseases, cancer, and neurodegenerative diseases, and uniquely addresses unmet medical needs.

ACROBiosystems Group, founded in 2010 and listed in 2021, is a biotechnology company aimed at being a cornerstone of the global biopharmaceutical and health industries by providing products and business models innovation.

Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.

Aspeya, owned by Philip Morris International, operates independently and utilizes Fertin Pharma's oral technology platform. Fertin Pharma, a wholly owned subsidiary of Aspeya, is a CDMO that develops and manufactures innovative oral and intra-oral delivery systems.

Biotech in the Autoimmune/Fibrosis Therapeutics Space.

Ymmunobio AG is a preclinical stage biotechnology company developing first in class assets for the treatment of solid tumors.

Lucerna Chem is one of the leading distributors for life science products in Switzerland, providing high quality reagents and kits from more than 70 suppliers for both research and diagnostics. We conveniently supply our customers with a variety of 4 Mio. products in simple domestic shipments.

Aurealis Therapeutics is a Swiss-Finnish Cell and Gene Therapy Platform Company. Our multi-target scalable low COGS products, based on genetically engineered lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers - Cancers - Ovarian, Peritoneal

Based in Epalinges, Pilatus Biosciences focuses on developing a first-in-class antibody targeting metabolic checkpoints. The company is transforming cancer treatment by developing innovative therapies that strengthen the immune system to fight cancer.

CROss Alliance® is a Swiss CRO specialised in early clinical development. With more than 500 trials performed at CROSS phase I unit or in selected EU sites, we are experts in PK, bioequivalence, first in man, tolerability studies including cardiac safety and efficacy models in healthy volunteers.

Atopia Therapeutics is developing a revolutionary treatment for allergic diseases such as atopic dermatitis, allergic asthma, food allergies and hay fever based on the discovery that a bacterium present in the human stomach produces a protein that protects us from these diseases.

NovaGo Therapeutics focuses on two regeneration promoting therapeutics aimed at restoring nerve fibre connections in acute spinal cord injury(SCI) and retinal vasculature in diabetic retinopathy(DR), Ph1b clinical trial for SCI was started in Dec 2024. Ph1b studies in DR are planned for end 2025.

NXI Therapeutics is committed to creating tomorrow’s disruptive immunotherapies for T cell-mediated autoimmune diseases and transplantation by coronin 1 modulation. NXI’s unique approach enables an auto- & allo-selective immunomodulation that retains immunocompetence against infections and cancer.

ZETA is an end-to-end solution provider and innovation leader for pharma & biotech and specializes in the design, automation, and qualification of customer-specific systems for pharmaceutical manufacturing. ZETA is an EPCMv contractor, drives digtialization and develops decarbonization strategies.

TissueLabs is a Swiss biotech pioneering biofabrication, developing 3D bioprinters, tissue-specific hydrogels, and engineered tissues. Supporting research, drug testing, and regenerative medicine, its long-term vision is to create the first transplantable bioartificial heart.

InCephalo is a preclinical stage biotech company with a compartment locked (CLocked) technology. InCephalo is positioning itself as a CLocked Fc-Fusion Cytokine and antibody company. The company’s most advanced product at a proprietary IL-12 for local application of brain cancers.

therainnova AG provides strategic and operational regulatory affairs consulting for the biopharmaceutical industry in Europe. With expert leadership and a strong partner network, we offer end-to-end regulatory support, including due diligence, to maximize portfolio value.

Limula is a Life Science Tools company based in Lausanne, Switzerland. We combine cell therapy process development and precision engineering to offer a fully closed and automated platform for the production of CAR-T and other highly-personalised treatments.

Healiva’s Wound Care & Skin Diseases proprietary Platform Technology includes an end-to-end approach with enzyme technology and cell therapies for wound care and skin diseases. The platform can diversify into vitiligo management, skin regeneration or sports injury applications.

Bright Peak Therapeutics is a biotechnology company advancing a portfolio of multifunctional immunotherapies. We leverage our world-class protein engineering & conjugation platform to generate novel protein therapeutics for cancer and other indications. Bright Peak is located in Basel and San Diego.

Athebio develops ultra-stable biotherapeutics using proprietary Athebody® DARPin molecules with high affinity and specificity. We partner on radiotherapeutics, T cell engagers, targeted delivery (LNP/AAV/oligo) and affinity ligands, enabling breakthrough therapeutic strategies.

Zambon Biotech is part of the Zambon group, it is focused in growing the portfolio and pipeline of the Zambon group by entering into partnerships, acquiring assets and supporting their clinical development up to commercialization as well as licensing commercial stage assets.

Noema Pharma is a clinical-stage biotech pioneering a portfolio of disease-transforming therapeutics for CNS-mediated conditions.

A Swiss life science company, spin off of UZH developing personalized skin tissue therapy to treat skin defects and beyond.

EsoCap AG is developing a unique targeted delivery platform technology for the treatment of patients with diseases of the esophagus. EsoCap recently successfully completed the double-blind, randomised, placebo-controlled Phase II ACESO study in the lead indication eosinophilic esophagitis (EoE).

Labatec is a privately owned Swiss-based pharmaceutical company with more than 50 years of experience in delivering high quality products to the European and Emerging Markets. Covering both the hospital and retail sectors, we have a portfolio of over 65 products and a growing geographic footprint.

AMYRA is developing a unique enzyme combination for curative care of Celiac Disease and Non-Celiac Gluten Sensitivity (NCGS), which represent major public health issues. AMYRA’s products have the potential to establish the standard of care and majorly impact the lives of affected people.

Vaderis Therapeutics AG is a clinical stage biotech focussing on treatment of rare diseases caused by vascular malformations. The company was founded in 2019 in Basel, Switzerland, and closed a Series A investment of CHF 18.1 Mio in 2020.

Novochizol SA researches and develops applications of Novochizol, a unique chitosan nanoparticle technology that yields different carriers of small molecules, peptides, nucleic acids and proteins for sustained, localized delivery to any living tissue, with intracellular targeting potential.

Rhizen is Swiss HQ biotech focused on discovery & development of innovative, small molecule drugs for the treatment of cancer & inflammatory diseases. The company has demonstrated leadership of the PI3K space and has a deep pipeline of novel differentiated assets across various stages of development.

GlycoEra is developing biologics to selectively degrade autoimmune disease causing circulating proteins rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies.

Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. We invest in companies in Switzerland or abroad that are active in the field of life sciences. We value strong founding teams and high-quality science.

MUVON is a Swiss, clinical stage biotech company with the goal of revolutionizing the treatment of diseases caused by muscle damage or degradation through the use of the patients' own cells. Our initial area of focus is the treatment of stress urinary incontinence in women (PhII completed)

Spin-off from EPFL developing precision gene therapies for Amyotrophic Lateral Sclerosis (ALS). ALS pathogenic mechanisms support that non-neuronal cells play a key role in this disease, through reshaping neuronal synaptic connections.

Parexel is focused on the development of innovative new therapies to improve the world’s health. We do this by providing a suite of groundbreaking biopharmaceutical development services that help customers across the globe transform scientific discoveries into new treatments for patients. From clinical tria

A Swiss microbiota biotherapeutics and mucosal vaccines company with two technology platforms: ApyraVax for the generation of innovative mucosal vaccines; ApyraMed with indications in IBD, dysbiosis induced by antibiotic treatments and unhealthy diet, and as enhancer in cancer immunotherapy.

Centenara is an integrated biotechnology platform company that develops and improves therapies and technologies to promote healthy aging and prolong lifespan. We provide start-up coaching and funding to entrepreneurial scientists to co-create therapies that benefit our aging population.

Holding, management consulting & strategy advisory focused on biotech, medtech, nutraceuticals and health services. Our strong knowledge of international competitive and synergistic landscape and our large network of strategic partners help our clients to expand into new jurisdictions and markets.

FoRx Therapeutics is a recently incorporated privately-held company based in Basel, Switzerland. FoRx Therapeutics focuses on drugging key molecular targets involved in the DNA Replication Stress, as a new approach in the development of targeted anticancer drugs.

Gut-Restricted Metabolic Therapies Validated Platform with 3 Preclinical Proof of Concepts Established as a pivate company (AG) in Basel in 2019 Secured a Partnership with Nestlé Health Science for one asset Raised CHF 10M in equity and non-dilutive funding Raising Series A

GliaPharm is a Swiss biotechnology company developing treatments for neurological disorders. The company has developed a proprietary platform and pipeline of molecules targeting brain glial cells to restore brain metabolism deficits in neurological diseases linked to brain metabolism dysfunction.

Alentis Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies targeting claudin-1 for a range of fibrosis and oncology indications. We are rapidly advancing our pipeline of antibodies and antibody-drug conjugates through clinical development.

OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and urinary tract infections, also active in the treatment of vascular diseases.

SOTIO is a biotech company building a diverse portfolio of oncology products through its own R&D, collaborations, in-licensing, investments, M&A. SOTIO is conducting multiple Phase I to III clinical trials targeting various types of cancer and has facilities in Europe and the US.